



1/4

SEQUENCE LISTING

<110> ONCOTHERAPY SCIENCE, INC.
JAPAN AS REPRESENTED BY THE PRESIDENT OF THE UNIVERSITY OF TOKYO

<120> Methods for damaging cells using effector functions of anti-FAM3D antibodies

<130> ONC-A0407-US

<160> 2

<170> PatentIn version 3.1

<210> 1
<211> 1322
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (298).. (972)
<223>

<400> 1

tcctcaaagg aggggcagag cctgcgcagg gcaggagcag ctggcccact ggcggcccgc	60
aacactccgt ctaccctct gggcccactg catctagagg agggccgtct gtgaggccac	120
taccctcca gcaactggga ggtgggactg tcagaagctg gcccagggtg gtggtcagct	180
gggtcaggga cctacggcac ctgctggacc acctgcctt ctccatcgaa gcagggaagt	240
gggagcctcg agccctcggg tggaagctga cccaagcca cccttcacct ggacagg	297
atg aga gtg tca ggt gtg ctt cgc ctc ctg gcc ctc atc ttt gcc ata	345
Met Arg Val Ser Gly Val Leu Arg Leu Leu Ala Leu Ile Phe Ala Ile	
1 5 10 15	
gtc acg aca tgg atg ttt att cga agc tac atg agc ttc agc atg aaa	393
Val Thr Thr Trp Met Phe Ile Arg Ser Tyr Met Ser Phe Ser Met Lys	
20 25 30	
acc atc cgt ctg cca cgc tgg ctg gca gcc tcg ccc acc aag gag atc	441
Thr Ile Arg Leu Pro Arg Trp Leu Ala Ala Ser Pro Thr Lys Glu Ile	
35 40 45	

cag gtt aaa aag tac aag tgt ggc ctc atc aag ccc tgc cca gcc aac	489
Gln Val Lys Lys Tyr Lys Cys Gly Leu Ile Lys Pro Cys Pro Ala Asn	
50 55 60	
tac ttt gcg ttt aaa atc tgc agt ggg gcc gcc aac gtc gtg ggc cct	537
Tyr Phe Ala Phe Lys Ile Cys Ser Gly Ala Ala Asn Val Val Gly Pro	
65 70 75 80	
act atg tgc ttt gaa gac cgc atg atc atg agt cct gtg aaa aac aat	585
Thr Met Cys Phe Glu Asp Arg Met Ile Met Ser Pro Val Lys Asn Asn	
85 90 95	
gtg ggc aga ggc cta aac atc gcc ctg gtg aat gga acc acg gga gct	633
Val Gly Arg Gly Leu Asn Ile Ala Leu Val Asn Gly Thr Thr Gly Ala	
100 105 110	
gtg ctg gga cag aag gca ttt gac atg tac tct gga gat gtt atg cac	681
Val Leu Gly Gln Lys Ala Phe Asp Met Tyr Ser Gly Asp Val Met His	
115 120 125	
cta gtg aaa ttc ctt aaa gaa att ccg ggg ggt gca ctg gtg ctg gtg	729
Leu Val Lys Phe Leu Lys Glu Ile Pro Gly Gly Ala Leu Val Leu Val	
130 135 140	
gcc tcc tac gac gat cca ggg acc aaa atg aac gat gaa agc agg aaa	777
Ala Ser Tyr Asp Asp Pro Gly Thr Lys Met Asn Asp Glu Ser Arg Lys	
145 150 155 160	
ctc ttc tct gac ttg ggg agt tcc tac gca aaa caa ctg ggc ttc cgg	825
Leu Phe Ser Asp Leu Gly Ser Ser Tyr Ala Lys Gln Leu Gly Phe Arg	
165 170 175	
gac agc tgg gtc ttc ata gga gcc aaa gac ctc agg ggt aaa agc ccc	873
Asp Ser Trp Val Phe Ile Gly Ala Lys Asp Leu Arg Gly Lys Ser Pro	
180 185 190	
ttt gag cag ttc tta aag aac agc cca gac aca aac aaa tac gag gga	921
Phe Glu Gln Phe Leu Lys Asn Ser Pro Asp Thr Asn Lys Tyr Glu Gly	
195 200 205	
tgg cca gag ctg ctg gag atg gag ggc tgc atg ccc ccg aag cca ttt	969

Trp Pro Glu Leu Leu Glu Met Glu Gly Cys Met Pro Pro Lys Pro Phe
 210 215 220

tag ggtggctgtg gctcttctc agccaggggc ctgaagaagc tcctgcctga 1022

cttaggagtc agagcccggc aggggctgag gaggaggagc aggggggtgct gcgtggaagg 1082
 tgctgcaggt ccttgcacgc tgtgtcgcgc ctctcctcct cggaacaga accctcccac 1142
 agcacatcct acccggaaga ccagcctcag agggtccttc tggaaccagc tgtctgtgga 1202
 gagaatgggg tgctttcgtc agggactgct gacggctggt cctgaggaag gacaaactgc 1262
 ccagacttga gcccaattaa attttatttt tgctggtttt gaatgaaaaa aaaaaaaaaa 1322

<210> 2
 <211> 224
 <212> PRT
 <213> Homo sapiens

<400> 2
 Met Arg Val Ser Gly Val Leu Arg Leu Leu Ala Leu Ile Phe Ala Ile
 1 5 10 15

Val Thr Thr Trp Met Phe Ile Arg Ser Tyr Met Ser Phe Ser Met Lys
 20 25 30

Thr Ile Arg Leu Pro Arg Trp Leu Ala Ala Ser Pro Thr Lys Glu Ile
 35 40 45

Gln Val Lys Lys Tyr Lys Cys Gly Leu Ile Lys Pro Cys Pro Ala Asn
 50 55 60

Tyr Phe Ala Phe Lys Ile Cys Ser Gly Ala Ala Asn Val Val Gly Pro
 65 70 75 80

Thr Met Cys Phe Glu Asp Arg Met Ile Met Ser Pro Val Lys Asn Asn
 85 90 95

Val Gly Arg Gly Leu Asn Ile Ala Leu Val Asn Gly Thr Thr Gly Ala
 100 105 110

Val Leu Gly Gln Lys Ala Phe Asp Met Tyr Ser Gly Asp Val Met His
 115 120 125

Leu Val Lys Phe Leu Lys Glu Ile Pro Gly Gly Ala Leu Val Leu Val
130 135 140

Ala Ser Tyr Asp Asp Pro Gly Thr Lys Met Asn Asp Glu Ser Arg Lys
145 150 155 160

Leu Phe Ser Asp Leu Gly Ser Ser Tyr Ala Lys Gln Leu Gly Phe Arg
165 170 175

Asp Ser Trp Val Phe Ile Gly Ala Lys Asp Leu Arg Gly Lys Ser Pro
180 185 190

Phe Glu Gln Phe Leu Lys Asn Ser Pro Asp Thr Asn Lys Tyr Glu Gly
195 200 205

Trp Pro Glu Leu Leu Glu Met Glu Gly Cys Met Pro Pro Lys Pro Phe
210 215 220